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Abstract 
 
 
 
IDENTIFYING FUNCTIONAL VARIATION IN SCHIZOPHRENIA GWAS LOCI BY 
POOLED SEQUENCING 
 
Erik Kristen Loken, B.S. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2014 
 
Director: Brien P. Riley, Ph.D. 
Associate Professor, Departments of Psychiatry and Human and Molecular Genetics 
 
Schizophrenia demonstrates high heritability in part accounted for by common simple 
nucleotide variants (SNV), rare copy number variants (CNV) and, most recently, rare SNVs 
Although heritability explained by rare SNVs and CNVs is small compared to that explained by 
common SNVs, rare SNVs in functional sequences may identify specific disease mechanisms. 
However, current exome methods do not capture a large proportion of potentially functional 
bases where rare variation may impact disease risk: as much as two-thirds of conserved 
sequences lie outside the exome in non-coding regions of cross-species evolutionary constraint. 
We reasoned that the candidate loci from the Psychiatric Genomics Consortium Phase 1 (PGC-1) 
schizophrenia study represent good target loci to test for the impact of rare SNVs in non-coding 
constrained regions. We developed custom reagents to capture mammalian constrained non-
coding regions, exons, and 5’- and 3’-untranslated regions (UTRs) in the 12 PGC-1 loci for 
pooled sequencing in 912 cases and 936 controls. Compared to our coding targets, our noncoding 
targets contain substantially more highly conserved bases (46,412 vs. 31,609) and variants (390 
vs. 193). Using C-alpha to detect excess variance due to aggregate risk increasing or decreasing 
rare SNV effects, we identified signals attributable to alleles with MAF < 0.1% in both coding 
sequences and in functional non-coding sequences, including variants within ENCODE 
transcription factor binding sites, DNase hypersensitive regions, and histone modification sites in 
neuronal cell lines. We also observed significant excess risk-altering variation in the CUB 
domain of CSMD1, a gene expressed in the developing central nervous system. These results 
support the hypothesis that common and rare variants in the same loci contribute to 
schizophrenia risk, but highlight the need to expand capture strategies in order to detect trait-
relevant sequence variation in a broader set of functional sequences.  
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Introduction 
 
Relevant Background 
Schizophrenia is an idiopathic, complex mental disorder with a lifetime risk of 0.4% 
(Lichtenstein et al., 2006; Saha, Chant, Welham, & McGrath, 2005). The onset of the disease is 
typically the early to mid-twenties for males and late twenties for females and can present either 
acutely with onset of a psychotic episode or with a longer prodromal phase. Schizophrenia as a 
syndrome was first described as “dementia praecox” by Emil Kraepelin (Kraepelin, 1899). He 
was the first to recognize the disease as separate from bipolar disorder or, as he called it, manic-
depression. To Kraepelin, the negative symptoms, those that reflect a loss of normal functions, 
including avolition, anhedonia, alogia, and blunted affect were the most relevant in 
distinguishing schizophrenia. Now the positive symptoms, those that reflect an excess or 
distortion of normal functions, including delusions, hallucinations, and disorganized speech, are 
given far more weight. Avolition describes the lack of initiation in goal-directed behavior, 
anhedonia is the lack of pleasure, alogia is the lack of fluency of thought and speech and blunted 
affect is a reduction in the range and intensity of emotional expression. Delusions are distortions 
of inferential thinking, hallucinations are distortions in perceptions and disorganized speech is a 
distortion in language. According to the DSM-5 (A. P. A. American Psychiatric Association, 
American Psychiatric Association D. S. M. Task Force, 2013), at least one positive symptom 
must be present during a one-month period in addition to another positive symptom, catatonia, or 
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negative symptom and the disturbance must be present for six months to diagnose schizophrenia. 
Previously, the DSM-IV (A. P. A. American Psychiatric Association, American Psychiatric 
Association Task Force on D. S. M. I. V., 2000) included five subtypes (paranoid, disorganized, 
catatonic, undifferentiated and residual), but as of the DSM-5 these subtypes are not included.  
 Schizophrenia has a very high heritability, established as 0.81 in twins (Sullivan, 
Kendler, & Neale, 2003) and 0.64 in a study of the Swedish population (Lichtenstein et al., 
2009). Further evidence of its heritability is a strong sibling recurrence risk of 8.55 (Lichtenstein 
et al., 2006). Schizophrenia has a high genetic correlation with bipolar disorder (0.68), major 
depressive disorder (0.43), and a lower genetic correlation with autism spectrum disorder (0.16) 
(Lee et al., 2013). These correlations have been supported by data from more recent studies 
detailed in this chapter in the form of joint and independent associations of loci with multiple 
psychiatric disorders. 
Despite the evidence for high heritability, monozygotic twin (MZ) concordance is only 
48%, suggesting that genetic risk factors do not entirely explain schizophrenia and that 
environmental risk factors are also important (Onstad, Skre, Torgersen, & Kringlen, 1991). The 
number of environmental and non-genetic risk factors studied and found contributing to 
schizophrenia is numerous, including paternal age (Petersen, Mortensen, & Pedersen, 2011), 
season of birth (J. J. McGrath & Welham, 1999), famine (St Clair et al., 2005), cannabis use 
(Hill, 2014), urban birth (J. McGrath & Scott, 2006), migration (Cantor-Graae & Selten, 2005), 
and prenatal infection (Khandaker, Zimbron, Lewis, & Jones, 2013). A meta-analysis of the 
prenatal maternal influenza infection literature has found no evidence of contributions to 
schizophrenia risk from the 1957 pandemic of influenza (Selten, Frissen, Lensvelt-Mulders, & 
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Morgan, 2010), but the prenatal infections Toxoplasma gondii and herpes simplex virus (HSV-2) 
show some effect (Brown & Derkits, 2010; Khandaker et al., 2013).  
Environmental risk factors are divided into common environmental factors to which both 
twins are exposed, and unique environmental factors to which twins are independently exposed. 
Common environmental risks are estimated by twin studies to represent 11% of the variance for 
schizophrenia while unique environmental factors are estimated to represent the remainder of the 
variance, 8% (Sullivan et al., 2003). Paternal age, season of birth, famine, urban birth and 
prenatal infection represent common environmental risk factors. Cannabis use and migration, 
may represent unique environmental risk factors. The examples listed that would contribute to 
the relatively low twin concordance are cannabis use, migration, measurement error (included in 
unique environment), and unknown unique environmental risk factors. Future studies 
investigating the environmental causes of schizophrenia will use prospective birth cohort studies 
instead of ecological and retrospective designs. By incorporating genotypes with environmental 
data, it is possible significant gene by environment interaction could be found (Brown, 2011), 
explaining low MZ concordance. 
 
Linkage and Candidate Genes 
These findings have inspired a large molecular genetics effort to identify the source of 
heritability. Pedigree analysis showed no evidence for one-locus mendelian transmission of 
schizophrenia (Elston, Namboodiri, Spence, & Rainer, 1978). This lack of evidence for a single 
causal locus and the swift drop in recurrence risk from monozygotic twins (52.1) to siblings (8.6) 
and offspring (10), suggested a multilocus model for heritability (Risch, 1990). This led to a 
large number of linkage studies searching for what investigators thought would be a few loci 
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responsible for schizophrenia. Early studies found no loci in linkage with schizophrenia (Kendler 
& Diehl, 1993), but later studies point to weak linkage at 22q12-q13, 8p22-p21, 6p24-p22, 
13q14.1-q32, 5q21-q31, 10p15-p11, 6q21-q22, 15q13-q14 and 20q11-q22 (McGuffin, Tandon, 
& Corsico, 2003) (Riley, 2004) with minimal agreement between studies. Positional loci 
suggested from these findings include NRG1, G72, DAAO, DTNBP1, and COMT, and an 
additional linkage discovery that was named Disrupted-In-Schizophrenia-I (DISC1) (Ishizuka, 
Paek, Kamiya, & Sawa, 2006) (Chubb, Bradshaw, Soares, Porteous, & Millar, 2008). The 
estimated effect sizes from linkage that were found were relatively small, and the positional 
candidate loci did not produce any significant variants on follow-up (Kirov, O'Donovan, & 
Owen, 2005). For the sample sizes collected, the lack of strong linkage in schizophrenia suggests 
that no locus existed with a recurrence risk > 3 (Owen, Craddock, & O'Donovan, 2005). 
 
Theoretical Candidate Genes 
Theoretical candidate genes for schizophrenia such as the dopamine receptors DRD3 and 
DRD2, the serotonergic receptor HTR2A, and the glutamatergic gene GRM3 have been studied 
and proposed as candidate genes because of their role in systems thought to be perturbed in 
schizophrenia, but until recently there has been a complete lack of any robust findings from these 
candidates (Kirov et al., 2005). More recently, evidence for theoretical candidate loci impacting 
schizophrenia has been found. The second phase of the Psychiatric Genomics consortium (PGC-
2) genome-wide association study (GWAS) (S. W. G. o. t. P. G. Consortium, 2014), a large 
study of 36,989 schizophrenia cases and 113,075 controls, found associations in DRD2, the 
dopamine receptor target for antipsychotic drugs, and genes involved in glutamatergic 
neurotransmission (GRM3, GRIN2A, SRR, GRIA1). Genes (GRM5, PPEF2, and LRP1B) that 
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encode protein products associated with the glutamate receptor N-methyl-D-aspartate receptor 
(NMDAR) have been found to have rare protein-altering variants in five schizophrenia pedigrees 
(Timms et al., 2013) 
 
Genome-Wide Association Studies 
 An early GWAS (Stefansson et al., 2009) of 2,663 schizophrenia cases and 13,498 
controls found associations in the Major Histocompatibility Complex (MHC) of chromosome 6, 
and the genes TCF4 and NRGN. Compared to other GWAS at these sample sizes, the results 
were not very impressive (W. T. C. C. Consortium, 2007). An additional study (Purcell et al., 
2009) of 3,322 schizophrenia cases and 3,587 controls found associations for MYO18B, the 
MHC region, ZNF804A, and six imputed human leukocyte antigen (HLA) alleles. The MHC 
region included over 450 single nucleotide polymorphisms (SNPs) across several Megabases 
(Mb). To analyze the GWAS signal for polygenicity, the authors summed odds-ratio (OR) 
weighted allele counts of independent variants per individual, and compared the scores of cases 
and controls. The aggregation of the signals for a great number of alleles of a small and neutral 
effect explained 3% of the variance for schizophrenia. This result indicated that although few 
loci had been observed through GWAS, causal variants were distributed throughout the genome 
at lower effect sizes, and that increasing sample size could lead to the discovery of more loci. 
The most successful published efforts so far have been the very large collaborative efforts of the 
Psychiatric Genomics Consortium (PGC) GWAS to analyze large schizophrenia samples (Ripke 
S, 2011) (Ripke et al., 2013). The PGC-1 schizophrenia GWAS of 9,394 cases and 12,462 
controls identified 8 loci by peak significant SNPs, MIR137, PCGEM1, TRIM26, CSMD1, 
MMP16, CNNM2-NT5C2, STT3A and CCDC68-TCF4 (hyphens included for loci with multiple 
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genes). In addition to these loci the authors combined the schizophrenia cases with 16,374 
bipolar disorder cases for a joint association study, finding ANK3, CACNA1C and ITIH3-ITIH4 
associated with the combined disorders. SNPs were intragenic to their loci except for PCGEM1 
(343 kb distance to nearest gene), MMP16 (421 kb), STT3A (1 kb) and CCDC68 (126 kb). A 
peak significant SNP was intragenic to TCF4, a locus previously implicated in schizophrenia 
(Steinberg et al., 2011). MIR137 was a novel and interesting result for schizophrenia in that it 
encodes a microRNA (miRNA) that is predicted to target four of the other significant loci in the 
study (TCF4, CACNA1C, CSMD1 and C10orf26). An additional study (Ripke et al., 2013), 
combining PGC-1 with a Swedish national sample of 5,001 cases and 6,243 controls, expanded 
the significant loci to 22, of which 13 were new. This study represents the most up-to-date peer-
reviewed results for common variation in schizophrenia. Using Genome-wide Complex Trait 
Analysis (GCTA) (Yang, Lee, Goddard, & Visscher, 2011), a method to estimate the variance in 
liability explained by all SNPs, researchers estimated SNP heritability to be 0.27, assuming a 
population risk of 0.004 (Lichtenstein et al., 2006), and 0.33, assuming a population risk of 0.01. 
The upper bound for schizophrenia heritability is 0.64 to 0.81, based on population and twin 
evidence, and the lower bound for schizophrenia SNP heritability is 0.27 to 0.33, using a 
population risk of 0.004 or 0.01. These results suggest that between one-third and one-half of 
schizophrenia heritability comes from common SNPs and at least half of the heritability of 
schizophrenia is left to be explained by other sources. A number of sources of this additional 
heritability have been suggested and studied intensively, including rare SNPs/indels (SNVs) 
identified by sequencing, CNVs identified directly from array comparative genomic 
hybridization (aCGH) or indirectly from intensity data on GWAS arrays, gene-environment 
interactions (GxE) (Iyegbe, Campbell, Butler, Ajnakina, & Sham, 2014; Maric & Svrakic, 2012; 
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Modinos et al., 2013; Svrakic, Zorumski, Svrakic, Zwir, & Cloninger, 2013), and gene-gene 
interactions (GxG or epistasis) (Chiesa et al., 2013; Nicodemus et al., 2010; Won et al., 2014). 
 The PGC-2 schizophrenia study (S. W. G. o. t. P. G. Consortium, 2014) is currently in 
submission. It expands the samples size to 36,989 schizophrenia cases and 113,075 controls. 
This is the largest molecular genetics study of schizophrenia or any other neuropsychiatric 
disorder and it found 108 distinct associated loci, 83 of which were not previously observed in 
schizophrenia. It is the first to strongly implicate DRD2, the target of antipsychotic 
pharmaceuticals used to treat schizophrenia. It also implicates genes involved in glutamatergic 
neurotransmission (GRM3, GRIN2A, SRR, GRIA1). More associations (CACNAB2 and 
CACNA1I) in voltage gated calcium channel subunits were observed including CACNA1C. 
Associations in active enhancers from 56 different tissues and cell lines showed significant 
enrichment not only in brain, but also tissues with immune functions such as the CD19 and 
CD20 B-lymphocyte cell lines. 
 
Copy Number Variants 
 Rare variants implicated in schizophrenia first came in the form of CNVs (Rees et al., 
2014) (Walsh et al., 2008). Many of these studies were not measuring heritable contributions 
from CNVs because they focused on de novo mutations (Malhotra et al., 2011) (Stefansson et al., 
2008). 22q11.2 deletion syndrome, also known as velocardiofacial syndrome or DiGeorge 
syndrome was found to be primarily de novo in newly diagnosed patients, with 90% of the 
deletions being de novo and 10% being inherited (Bassett, Marshall, Lionel, Chow, & Scherer, 
2008). Some standing CNVs affecting schizophrenia, and inherited 2p16.3 deletion affecting 
NRXN1(Kirov et al., 2008), duplications of 16p13.1 (Ingason et al., 2011), and duplications of 
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16p11.2 (McCarthy et al., 2009), have been discovered. Heritable CNVs show minor allele 
frequency (MAF) ranges of 0.30% in cases for the 16p11.2 duplication compared to 0.03% in 
controls (8.4 OR) and 0.12% in cases for the 16p13.1 duplication compared to 0.04% in controls 
(3.27 OR). Examples of replicated signals in deletions show MAF between 0.23-0.32% for 
1q21.1, with an OR ranging 6.6-14.8, and 0.17-0.3% MAF for 15q13.3, with an OR ranging 
11.5-17.9 (Sebat, Levy, & McCarthy, 2009). These loci are nonspecific risk factors for other 
disorders, such as developmental delay and congenital malformations for 1q21.1 and generalized 
epilepsy and mental retardation for 15q13.3 (Sebat et al., 2009). In addition, 16p11.2 deletions 
are more common in autism and developmental delay (0.78% MAF, OR 38.7) while not at all 
more common in schizophrenia. CNVs have low MAFs, high ORs, and pleiotropic effects. The 
presence of CNVs impacting schizophrenia risk in addition to GWAS data support a complex 
genetic architecture with rare and common variation. 
 
Exome Studies 
 The first exome studies of schizophrenia were published in the last few years. One of the 
first found an elevated de novo mutation rate in 14 schizophrenia trios (Girard et al., 2011). 
Another published concurrently a de novo design of 53 case and 22 control trios, identified 40 de 
novo mutations in cases, one of which was in DGCR2, a gene located in the 22q11.2 DiGeorge 
Syndrome locus (B. Xu et al., 2011). Using rare inherited variants for comparison, the authors 
observed an excess of non-synonymous variants that were de novo. This study was later 
expanded to 231 schizophrenia trios and 34 control trios (B. Xu et al., 2012). The excess signal 
from de novo nonsynonymous SNVs was replicated and these variants were more enriched in 
genes with greater prenatal expression. A study of 166 cases and 307 controls (Need et al., 2012) 
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with a strategy using a follow-up cohort of 2,756 cases and 1,932 controls for further testing 
found no significantly associated SNVs. With the relatively small sample size, there was only 
power to detect variants at 1% MAF with a relative risk of 6 for a nominal association leading to 
follow-up. One exome study of five large schizophrenia pedigrees (Timms et al., 2013) found 
rare protein-altering variants implicating glutamatergic neurotransmission. Protein-altering 
variants from one of three genes, GRM5, PPEF2, and LRP1B, whose protein products are 
associated with NMDAR, were discovered in all five pedigrees. A recent exome study 
(McCarthy et al., 2014) of 57 sporadic and familial schizophrenia trios found a 3.5-fold increase 
of de novo mutations in the sporadic probands compared to the familial probands. These de novo 
mutations were found in excess in genes with a high estimated probability of haploinsufficiency. 
An overlap of loci with de novo mutations was observed with autism (AUTS2, CHD8 and 
MECP2) and intellectual disability (HUWE1 and TRAPPC9).  
A new round of larger exome studies has been published for schizophrenia. The first is a 
study of de novo mutations from trios (Fromer et al., 2014). The study authors acknowledge that 
they are using the same study design as many de novo CNV trio studies, but with exome 
sequencing they now have the resolution to identify single base de novo mutations that impact 
schizophrenia. Using data from 623 exomes from schizophrenia trios and 731 controls from 
published data sets, they did not identify any excess rate of de novo point mutations in 
schizophrenia probands. They were able to identify enrichment of nonsynonymous de novo 
mutations in genesets with independent evidence for involvement in schizophrenia. They also 
found an enrichment of loss-of-function mutations in genes identified in autism and intellectual 
disability studies of de novo variants. Certain genesets also had an enrichment of 
nonsynonymous mutations, most notably those encoding components of the activity-regulated 
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cytoskeleton-associated protein (ARC) complex, the NMDAR complex, and genes regulated by 
the fragile X mental retardation protein (FMRP). The authors targeted the first two sets for 
analysis because of the presence of de novo CNVs in the ARC and NMDAR complexes (Kirov 
et al., 2012). In addition to nonsynonymous mutations, the ARC and NMDAR complexes were 
also significantly enriched for loss-of-function de novo mutations in cases. FMRP and its targets 
are implicated by de novo mutations in autism (Iossifov et al., 2012) that specifically impact 
these brain-expressed genes related to synaptic function (Darnell et al., 2011). Because of its 
connection to autism and synaptic function, the authors hypothesized that de novo mutations 
would also be a factor for schizophrenia. They observed that nonsynonymous de novo mutations 
in FMRP target genes were significantly enriched in cases. There was also an enrichment of loss-
of-function de novo mutations in genes with excess loss-of-function de novo mutations found in 
autism and intellectual disability studies. The genes with loss-of-function de novo mutations in 
autism were also enriched for nonsynonymous de novo mutations in schizophrenia. 
 The other major exome study published in the same issue of Nature was a case-control 
study of exomes sequences from 2,536 schizophrenia cases and 2,543 controls (Purcell et al., 
2014). The authors of this study and the trio study shared data and Purcell et al. were able to 
confirm the signal in the ARC complex for disruptive (nonsense, essential splice site and 
frameshift) singletons and < 0.5% MAF variants. The NMDAR complex association from 
Fromer et al. was not replicated. The genes implicated in the de novo SNV studies had an 
enrichment of < 0.5% MAF distruptive variation. Focusing on a composite geneset of loci 
previously implicated in schizophrenia by GWAS (Ripke et al., 2013), CNV(Kirov et al., 2012) 
(Sullivan, Daly, & O'Donovan, 2012), and de novo SNV studies (Girard et al., 2011; Purcell et 
al., 2014; B. Xu et al., 2012), the authors observed a significant enrichment of singleton and < 
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0.5% MAF disruptive variation in case samples. A significant enrichment of.< 0.1% MAF case 
variation was observed when including missense variants predicted to be damaging by multiple 
prediction algorithms in the test set. There was an enrichment of singleton disruptive variants for 
voltage-gate calcium ion channel genes, especially in CACNA1C, which was implicated as a 
joint bipolar disorder and schizophrenia risk locus in the PGC-1 analysis (Ripke S, 2011). 
Expanding their analysis to crossover points with autism studies the authors observed enrichment 
of case disruptive and nonsynonymous alleles in FMRP targets identified from mouse brain 
(Darnell et al., 2011) for < 0.1% MAF variation. FMRP targets identified from human kidney 
(Ascano et al., 2012) did not contain any case enrichment of disruptive variants, suggesting that 
for these FMRP targets the location of the targeting to the brain across species is more 
meaningful for testing than the targets across tissues but from the same species.  
 The exome studies build upon the previous GWAS and CNV studies, but are not 
definitive for the impact of rare variation in schizophrenia. Overall, the results point towards 
schizophrenia genes having brain functions, specifically synaptic network functions. There is 
overlap between bipolar disorder and schizophrenia both phenotypically and genotypically. 
Shared SNP-based coheritability for the two disorders is estimated to be 0.68 (Lee et al., 2013) 
and certain specific genes, such as the jointly associated voltage-gated calcium ion channel 
CACNA1C (Ripke S, 2011), have now been observed as independent associations for bipolar 
disorder (Ferreira et al., 2008) and schizophrenia (S. W. G. o. t. P. G. Consortium, 2014). In both 
the de novo SNV and the case-control exome studies, FMRP targets were identified as a source 
of rare variant enrichment, risk, and overlap with autism. The case-control exome study did not 
find enrichment in the common SNP loci from the GWAS studies. The test did have a suggestive 
p-value for disruptive MAF < 0.5% variants (0.0037) but this did not meet the significance 
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threshold based on multiple testing. The lack of rare variants impacting the common variant loci 
could be due to the relatively small samples size from the exome study, 2,536 exome cases 
compared to a meta analysis of 9,394 PGC-1 cases, and 5,001 Swedish cases.  
A final interesting component of the exome studies is their estimation of the variance of 
schizophrenia risk explained by polygene scores in an overlapping sample of 5,079 individuals 
due to SNPs (5.7%), rare CNVs (0.2%), and disruptive mutations (0.4%). The authors note that 
the rare CNVs and disruptive mutations explain an order of magnitude less variance that the 
SNPs. The authors admit that these estimates represent a conservative lower bound for the true 
estimates, as the disruptive mutations are only from the composite set (see above) which 
represents about 10% of the genome (~2,500 genes). Including the rest of the genome, more 
samples, and potentially a more relaxed set of variants beyond disruptive variation (nonsense, 
essential splice site and frameshift), should increase the variance explained by rare SNVs. Rare 
variation is observed less frequently than common variation, requiring larger sample sizes and 
effect sizes to detect associations. Samples sizes for exome studies so far have been an order of 
magnitude lower than for GWAS and exome sequencing in schizophrenia has yet to obtain a 
statistically significant signal for either a single allele or for alleles aggregated across a single 
gene. Increasing sample size to approximately the level now available in the largest GWAS of 
schizophrenia seems necessary to provide the power needed for identification of either single 
loci enriched for variation in cases or specific rare variants associated with schizophrenia. 
 
Non-coding Variation 
 It is important to consider why the exome and not the genome is the current standard for 
large sample sequencing studies. The cost for genome sequencing has dropped rapidly since 
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2001, but the rate of decrease has been less dramatic in the last two years with the estimated cost 
at about $4,008 as of January 2014 (Figure 1) (Wetterstrand, 2014). Exome sequencing using 
target capture (Asan et al., 2011) is far cheaper with recent rates quoted as low as $500 per 
exome (Perkel, 2013). Investigators reason that the most important part of the genome in which 
to look for variation are the coding regions. Some exome capture reagents also target UTRs and 
miRNA.  
 
Figure 1: The cost of whole genome sequencing over the years 
 
These approaches are missing potentially important target regions. A study of human 
evolutionary constraint by comparison of 29 mammalian genomes observed that at least 5% of 
the human genome is under purifying selection (Lindblad-Toh et al., 2011). Selection implies 
functionality of the underlying sequence, only 1.5% of which is coding in the human genome. As 
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much as two-thirds of constrained, likely functional sequences are non-coding and are therefore 
completely missed by exome studies. For a complex genetic disorder like schizophrenia with no 
observed single rare coding changes associated with disease, this could represent a critical 
amount of contributing variation. The Encyclopedia of DNA Elements (ENCODE) (Rosenbloom 
et al., 2013) study is a collaborative study with the goal of creating a complete catalog of 
functional elements for the human genome. As of 2013 it consists of 2,886 experiments from 
multiple sites made public by the University of California for download and use on its genome 
browser (Kent et al., 2002). The ENCODE project has identified regions in the human genome 
that include sites of modifications to histones which effectively increase or decrease local gene 
expression, sensitivity to DNase-I, indicating open chromatin and potential for transcription, and 
transcription factor binding sites. Data have been included in the ENCODE project from many 
cell lines, including those originating from glia and neurons that are most useful for the study of 
brain disorders like schizophrenia. Histone modifications sites, DNase-I hypersensitive sites, and 
transcription factor binding sites occupy largely non-coding regions not included in a traditional 
exome capture. Current capture reagents (even those including UTRs) do not include these 
potentially important functional sequences and are likely to be missing an important functional 
component of the genome. 
 
Common Variant Loci 
 A great amount of effort in sample collection, planning, and funding went into current 
exome studies. Two strategies can be used to reduce the scope of work and expense of 
identifying rare causal variation associated with disease: pooled sequencing (Futschik & 
Schlotterer, 2010) and targeting of smaller regions than the exome. In the pooled sequencing 
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approach, groups of samples are combined in equimolar amounts and sequenced as one sample. 
This allows library preparation costs, a significant component of sequencing costs, to be reduced 
by the factor of the pool size. Common variant loci have been hypothesized to also contain rare 
associated variation. This has been shown in inflammatory bowel disease (IBD) (Rivas et al., 
2011), which includes both Crohn’s disease and ulcerative colitis, autoimmune diseases of the 
whole digestive system and the colon, respectively. Rivas et al. used pooled targeted sequencing 
of 56 genes from common variant loci identified in GWAS to identify potentially causal rare 
variation in 350 cases and 350 controls. They identified 70 rare variants that cause a change to 
the proteins implicated in GWAS of IBD. This study strategy allows low cost sequencing of a 
reduced target area. Low cost sequencing allows a greater sample size to be sequenced and 
combined with the reduced target area, increasing the power of the study to detect effects of rare 
variation. Rivas et al. identified multiple rare variants through follow-up genotyping in 16,054 
Crohn’s disease cases, 12,153 ulcerative colitis cases, and 17,575 healthy controls, some 
protective and some damaging. The observation of protective rare variant for a disease is not 
isolated to IBD, having been observed in coronary heart disease (Cohen, Boerwinkle, Mosley, & 
Hobbs, 2006) and plasma low-density lipoprotein levels (Cohen, Pertsemlidis, et al., 2006).  
 
Aims 
 Taking this information in aggregate, it is clear that much of the heritability is from 
unknown sources (Manolio et al., 2009) (Lee, Wray, Goddard, & Visscher, 2011) and the large 
majority of heritability that is measurable is polygenic and spread throughout the genome at 
common and rare allele frequencies. The common variant loci from the PGC-1 schizophrenia 
study very likely represent the best candidate loci for unbiased follow-up in a targeted rare 
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variant study. Unlike the IBD study, we hypothesized that by including relevant non-coding 
variation identified in the study of 29 mammals (Lindblad-Toh et al., 2011) we would increase 
our functional target substantially compared to the coding sequence of these loci alone. We had 
access to 912 cases in our Irish Case-Control Study of Schizophrenia (ICCSS) and 936 
unscreened Irish controls from the Trinity Biobank for the study. We aimed to identify functional 
rare variation in the coding and non-coding sequences of the top schizophrenia common variant 
loci. To accomplish this goal, we adapted the pooled, targeted sequencing approach from Rivas 
et al. to reduce costs by focusing the target, while still maximizing sample size. Instead of using 
PCR amplification of exons, we used in-solution hybridization capture (Bansal, Tewhey, 
Leproust, & Schork, 2011) to reduce sample processing load and still be able to sequence many 
different targets within our loci. For analysis, we not only used Burden tests (Price et al., 2010), 
which allow for directionally specific aggregate effects, but also C-alpha (Neale et al., 2011), a 
test which measures bidirectional aggregate effects. This allows us to take advantage of the 
possibility of a similar observation in schizophrenia of not only damaging variants but protective 
variants like in IBD, coronary heart disease (Cohen, Boerwinkle, et al., 2006), and low-density 
lipoprotein levels (Cohen, Pertsemlidis, et al., 2006). Using all these techniques and all this 
knowledge, we aimed to detect rare variation impacting schizophrenia in common variant loci 
not only in coding regions, but also the two-thirds of potentially functional variation that is non-
coding with goals of improving the understanding of schizophrenia genetics in its top loci and 
schizophrenia genetics, generally. 
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Methods 
 
 
 
Sample Information 
 We selected 912 schizophrenia cases from the ICCSS and 936 unscreened Irish controls 
from the Trinity Biobank for sequencing. The ICCSS was collected by Kenneth Kendler of the 
Virginia Commonwealth University from 1999 to 2003 (Riley et al., 2010). Affected subjects 
were selected from inpatient and outpatient psychiatric facilities in the Republic of Ireland and 
Northern Ireland. Subjects were eligible for inclusion if they had a diagnosis of schizophrenia or 
poor outcome schizoaffective disorder by DSM-III-R criteria. Diagnoses were confirmed by a 
blind expert diagnostic review and subjects must have reported all four grandparents as being 
born in Ireland or the United Kingdom. The use of DSM-III-R maintained consistency with 
previous DSM-III-R era collections done by the group. Each proband completed a personal 
interview with a detailed family history. The control subjects are blood donors from the Trinity 
Biobank in Dublin.  Although not given a formal diagnostic interview, all control subjects deny 
any personal or family history of psychosis. The relatively low prevalence of schizophrenia 
(~1%) makes these donors suitable controls. The ethnic homogeneity of the sample avoids 
population stratification in our studies.  
 
Target Capture 
Agilent SureSelect Custom solution-based capture allows capture of custom designed 
regions of the genome. The small size array allowing up to 500kb of sequence was ideal for our 
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application. To define target intervals, we first examined linkage disequilibrium (LD) around 
associated SNPs from the PGC results using Haploview and HapMap data version 3 release 27 
from individuals of European descent, the Centre d'Etude du Polymorphisme Humain (CEPH) 
sample of Utah residents with ancestry from northern and western Europe (CEU), and Tuscan 
Italian (TSI) samples. The CEU and TSI samples were chosen to best approximate the PGC-1 
sample composition with the available HapMap ethnicities. Pairwise markers > 500 kb apart 
were ignored and individuals with > 50% missing genotypes were excluded. We included the 
associated SNPs from the schizophrenia analysis and the joint schizophrenia and bipolar 
association loci where bipolar and schizophrenia where analyzed as one phenotype (Table 1). 
The schizophrenia study loci are MIR137, PCGEM1, TRIM26, CSMD1, MMP16, CNNM2, 
NT5C2, STT3A, CCDC68, and TCF4. The joint targets are ITIH3/4, ANK3, and CACNA1C. The 
target interval is defined as the region with R2 > 0.8 with the associated SNP. If the interval 
overlaps part or all of one or more genes, then all exons and constrained sequence from those 
genes were included in the target set. For several loci, the LD interval did not overlap any gene 
(PCGEM, MMP16, CCDC68). The MMP16 region only contained the original associated SNP 
from the PGC analysis. These three loci only contributed to 520 bp (base pairs) of constrained 
regions total (Table 1). Because we were underpowered to detect association for the 3, we were 
left with 9 out of the 12 loci for locus testing. 
 Within these regions we selected all coding and UTR sequences in addition to regions 
from the 29 mammals paper (Lindblad-Toh et al., 2011) including human and primate 
accelerated regions, regulatory motif instances, peaks indicating constraint structure in promoters 
and, finally, SiPhy-omega and SiPhy-pi constrained regions with a logarithm of odds (LOD) 
score requirement of at least 7.325 for inclusion to allow the best regions within the constrained 
 19 
sequence space of 500kb. These regions were then used to design a SureSelect custom capture 
library consisting of 120 bp baits (Agilent Technologies, Santa Clara, CA) using SureDesign 
software with moderate masking of repeats. The final Agilent SureSelect target capture design 
included 84.5% of the non-coding regions that the 29 mammals study (Lindblad-Toh et al., 
2011) considered constrained at the 10% false discovery rate (FDR) level. 
 
Table 1: GWAS loci target Intervals  
Locus Chr. Association Total Target 
MIR137 1p21.3 SCH1 10232 
PCGEM1 2q32.3 SCH 140 
TRIM26 6p21-22 SCH 3888 
CSMD1 8p23.2 SCH 29399 
MMP16 8q21.3 SCH 1 
CNNM2 & NT5C2 10q24 SCH 26609 
STT3A 11q24.2 SCH 4846 
CCDC68 18q21.2 SCH 379 
TCF4 18q21.2 SCH 67448 
ITIH3/4 3p21.1 Joint2 18640 
ANK3 10q21.2 Joint 43303 
CACNA1C 12p13.33 Joint 31821 
Totals    236706 
1Schizophrenia association results. 2Results from joint bipolar and schizophrenia associations 
 
Library Preparation and Sequencing 
Samples were run on 1.5% agarose gels to check for the presence of high molecular 
weight DNA. Only samples with high molecular weight DNA (lanes 1-9 and 11-18, Figure 2) 
were included in this project; degraded samples (example in lane 10, Figure 2) were excluded. 
Nanodrop spectrophotometry was used to confirm sample purity using a 260/280 ratio of 1.8 to 
2.0. One round of PicoGreen (Life Technologies, Carlsbad, CA) dsDNA quantitation was 
performed to measure the concentration double stranded DNA only. After adjusting sample 
concentrations to 50 ng/µL of dsDNA we performed a second round of PicoGreen quantitation 
and adjusted concentrations to 23 ng/µL, the recommended shearing concentration for library 
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preparation. We then performed a third round of PicoGreen quantitation to determine the precise 
individual sample concentrations for equimolar pooling. 
 
 
Figure 2: Representative gel results for quality control of cases and controls. Here are 18 controls one of which is 
degraded (lane 10) and the rest of which contain high molecular weight DNA. The sample from lane 10 was too degraded 
to include in the study. 
 
We constructed pools of 24 case or 24 control subjects. Twenty-four samples per pool 
were ideal for several reasons. First, Illumina, our chosen sequencing platform has a nominal 1% 
error rate. Therefore 50 samples or 100 chromosomes would be the maximum allowable per pool 
to still allow detection of a singleton allele in the pool at or above the error rate. Reducing pool 
size to 24 samples (or 48 chromosomes) doubles the signal expected from a singleton allele and 
substantially improves detection of singleton alleles over errors in the pool. Second, we had 
reagents for 96 pools based on kit sizes from Agilent, which gave a minimum size of 20 samples 
per pool to include all selected subjects. Finally, 4 sets of 24 samples fit on a standard 96-well 
plate, which increases workflow efficiency and allows for spare capture reagents. We pooled 
each set of 24 case or control samples into equimolar pools basing the exact volume on the final 
PicoGreen concentration readings using robotic liquid handling to maximize accuracy. The final 
study sample included 38 case and 39 controls pools. 
We sheared 130 µL from each pool stock using the Covaris S2 instrument (Covaris, 
Woburn, MA) with a duty cycle of 10%, intensity of 5, 200 cycles per burst and the frequency 
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sweeping mode for 6 cycles of 60 seconds each to get a target peak base pair size of 150 to 200 
bp. We followed this with purification of the pool using Agencourt AMPure XP beads (Beckman 
Coulter Inc., Pasadena, CA). Every sheared pools size distribution was assessed using the 
Agilent 2100 Bioanalyzer with a DNA 1000 chip (see representative trace, Figure 3). Shearing 
leaves damaged ends to the double stranded DNA, so we followed this step with end repair using 
T4 DNA polymerase, Klenow DNA Polymerase, T4 Polynucleotide Kinase, and reagents from 
the SureSelect Library Prep Kit, followed by an additional AMPure XP purification. We added A 
bases to the 3’ end of the fragments for each pool using exo(-) Klenow fragment, dATP, and 
reagents from the SureSelect Library Prep Kit followed by an AMPure XP purification. We then 
ligated adapters to the pool fragments using T4 DNA Ligase and SureSelect Library Prep Kit 
reagents followed by AMPure XP purification. To produce enough library for hybridization we 
amplified the libraries for 5 cycles of PCR using Herculase II Fusion DNA Polymerase and 
SureSelect Library Prep Kit reagents. We then purified the pool libraries using AMPure XP and 
measured concentration and quality using a DNA 1000 chip on the 2100 Bioanalayzer. We dried 
the pools using a vacuum concentrator and reconstituted them with nuclease-free water at a 
concentration of 220 ng/µL for hybridization. 
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Figure 3: Representative trace of pool 56 after shearing using the Covaris S2. The peak is at 173 bp, between the targets 
of 150 and 200. 
 
 We preformed target capture using solution hybridization of pool library fragments with 
the 120 bp baits produced for the SureSelect Custom Capture. We denatured the concentrated 
pool libraries and then combined them with hybridization buffers. We added index blocking 
oligonucleotides to prevent index and adapter sequences from inhibiting hybridization between 
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the baits and the target sequence. We incubated the final hybridization mixture for 24 hours at 
65˚C with a heated lid at 105˚C.  
We biotinylated the hybridization baits, allowing selective capture of bait-target hybrid 
fragments using Dynabeads MyOne Streptavidin-coated T1 magnetic beads (Life Technologies, 
Carlsbad, CA). We mixed the Streptavidin T1 beads with the hybridization mixture and allowed 
it cool to room temperature while mixing for 30 minutes on a rotator followed by two washes 
using SureSelect Kit reagents. In the denaturation step of PCR, the library and bait disassociate 
and the library fragments move into solution. This allowed us to perform PCR directly from the 
beads in the PCR solution to amplify the library and add the index tags. We used Herculase II 
Fusion DNA Polymerase and a random selection of 77 of the 96 Illumina PCR Primer Indexes 
for the PCR reactions and we ran 16 cycles for each pool. We purified each pool using AMPure 
XP, which conveniently removes the used Dynabeads MyOne Streptavidin-coated T1 magnetic 
beads from solution, and analyzed for concentration and library quality using the DNA High 
Sensitivity Chip on the Bioanalyzer (see representative trace, Figure 4). 
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Figure 4: Representative trace of pool 56 after target capture and PCR. The peak is now above 300 bp, due to the addition 
of the adapters and index tags to the library. 
 
 We performed qPCR on each pool using the QPCR NGS Library Quantification Kit 
(Illumina, San Diego, CA) to measure the concentration of each pool for equimolar 
megapooling. To test the accuracy of megapool construction, we used these concentrations to 
make a test megapool of the post-capture library pools using robotic liquid handling and ran this 
test megapool on an Illumina MiSeq 150 bp paired-end run at the VCU core lab. We aligned the 
reads from this run using BWA (Li & Durbin, 2009) and we used the coverage results to adjust 
the 77 individual pool concentrations one more time to construct the final equimolar megapool. 
 25 
We sent the megapool to the VCU core lab for 103 bp paired-end sequencing on the Illumina 
HiSeq 2500 where it was cross loaded onto 5 lanes of the flowcell. 
 
Sequence Data Processing 
 After we received the raw reads from the core lab, we aligned the reads to the genome 
using BWA version 0.7.0 (Li & Durbin, 2009). BWA uses the Burrows-Wheeler transformation 
to allow quick alignment of the reads to the genome. We used the Genome Analysis Toolkit 
(GATK) version 2.5 (DePristo et al., 2011) to do local realignment of reads to reduce 
mismatches near indels. Each base in a sequencing experiment has a Phred quality score 
indicating the probability the base call is an error according to the formula ! = −10!"#!"! 
where P is the error probability and Q is the Phred score. The score is included as output from 
the sequencing platform’s internal software and can be improved using covariates and alignment 
information to recalibrate the scores. We performed base quality score recalibration using GATK 
using read group, reported quality score, cycle (base position in read), and context (dinucleotide 
and trinucleotide) to produce more accurate empirical quality scores for variant calling. 
 
Variant Calling 
 We called variants from the finalized realigned and recalibrated sequence data using 
CRISP (Bansal, 2010) (Comprehensive Read analysis for Identification of SNPs from Pooled 
sequencing), a variant caller developed specifically for read data from pooled sequencing. CRISP 
is able to call variants in pools by first comparing the allele count distribution across all the pools 
in the experiment using contingency tables. It then evaluates the probability that multiple non-
reference base calls at a locus are due to sequencing errors. To distinguish a sequencing error 
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from a real variant, it uses the distribution of alternate allele counts across the pools as a guide. If 
the distribution is similar across the pools, this is more likely to reflect sequencing error. 
Differences in the distribution of apparent allele counts across pools indicate varying allele 
counts in the pool and support the existence of a true variant at the site. CRISP also takes the 
sequencing error rate into account and computes a probability that a certain number of alternate 
alleles would be present at a site given sequencing error alone. The lower this probability, the 
greater the evidence for a true variant at the site. Finally, the number of chromosomes per pool is 
considered to ensure that the alternate allele frequency does not deviate too far below !!, where h 
is the number of haplotypes in the pool. If the frequency of alternate base calls at a site is much 
lower than expected using a binomial test, it is more likely that the signal represents sequencing 
error.  
 
Quality Control 
We conducted all data processing and analyses in R version 3.0.2 (R Core Team, 2013). 
We assigned hardcoded allele counts where the alternate allele count of the pool for a particular 
variant was assigned to the 푛 allele count for which its sequence read data alternate allele count 
was within !!" of !!" (48 chromosomes per pool). This method gives an approximation of the allele 
count for the pool based very simply on the allele count which most closely matches the read 
count data. Based on these data, we observed the metric singletons per pool showed serious 
outliers. We were concerned this may indicate spurious results resulting from potential problems 
during pooling and library preparation. We identified four pools, two case and two control, 
greater than the median number of singletons per pool (43) plus the standard deviation (51.25) 
(Figure 5). We filtered the four pools before final allele count calling and analysis. We filtered 
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variants based on quality score using the R package mclust version 4.2 (Chris Fraley, 2012). 
Mclust identified 8 clusters of quality scores for which a division between the first 3 and last 5 at 
a quality score of 875 represented an obvious division between low quality and high quality 
variants for filtering and maintaining for further analyses (Figure 6). Of the 9928 variants, we 
filtered 2736 based on quality score. For each pool we calculated the R2 between allele 
frequencies for 2,651 variants imputed from Affymetrix array genotypes using the 1000 
Genomes data to the pool allele frequencies based on read count for the variants in the pools. The 
median and standard deviation for the R2 values across the 77 pools were 0.9919 and 0.0087. We 
excluded four pools, one case and three controls, that were two standard deviations below the 
median (Figure 7). We were left with a total 69 pools, 35 case and 34 controls, equivalent to 
1,656 samples, 840 cases and 816 controls. 
 
Figure 5: Histogram of sample-wide singletons per pool with pools greater than the median plus standard deviation 
marked red. 
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Figure 6: Distribution of variant quality score with vertical red line representing division between filtered low quality 
variants (left) and maintained high quality variants (right) 
 
 
Figure 7: Each pool plotted with its imputed genotypes to pooled sequenced genotypes R2 and its proportion of pool with 
imputed data. Some samples included in the project did not have GWAS data for imputation. Filtered pools are in red. 
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Allele Count Calling 
We used a Bayesian method to assign exact allele counts for each variant per pool. We 
assigned the probability for the allele count for each pool according to the formula ! !""#"#!!"#$%! !!"#$%!!"!!""#) = ! ! !"#$%!!"!!""#! !!""#"#!!"#$%)!!(!!""#"#!!"#$%)!(!"#$%) . We calculated the 
probability that the read count for reference and alternate alleles in the pool occurred using the 
binomial distribution, taking into account the coverage level and number of alternate bases 
observed. We assumed there were 0 to 48 alternate alleles in the pool, ! = !"#$%!" , assigning 0 and 
48 alleles 0.5% and 99.5% probability, respectively. We used the binomial distribution to 
determine the probability that a particular pool has allele counts 0 to 48 given the average minor 
allele frequency across all the pools calculated from the alternate and reference read data. We 
selected the allele count per variant per pool with the highest probability as the true allele count 
and we saved the probabilities for each allele count for simulations during permutation 
significance testing. This allele count fine-tuning lowered the excess rate of intrapool multiple 
detection for certain rare alleles. For example, for experiment wide doubletons the hardcoded 
allele counts yields 103 doubleton variants out of 764 where both alleles are observed in a single 
pool. This is expected only 21 times according to the binomial distribution. For the probabilistic 
allele counts, intrapool doubletons only occur 44 times representing more than two-fold 
reduction in the deviation from expectation. The same trend in improvement is observed with 
tripletons (39 to 26, 18.0 expected) and quadrupletons (34 to 24, 15.3 expected) (Figure 8). 
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Figure 8: Counts per pool of study-wide doubletons, tripletons and quadrupletons with hardcoded allele counts 
(red) and Bayesian allele counts (blue). Bayesian counts are closer to the expected number found per pool (black line) 
 
Statistical Tests 
We used variable threshold C-alpha (Neale et al., 2011) and Burden (Price et al., 2010) 
testing. The strategy of the C-alpha test is to measure excess binomial variance in the distribution 
of allele counts between cases and controls for a set of variants. C-alpha measures general 
excesses of risk variation bidirectionally, for protective and damaging alleles. Burden testing 
measures excess enrichment of alleles for a set of variants in one direction, either increasing risk 
or decreasing risk for the variable in question. C-alpha and Burden tests will both detect excesses 
unidirectionally but for bidirectional effects in the same set of variants, the signal will be 
cancelled out for Burden testing and will be increased for C-alpha. Variable threshold tests allow 
the detection of signals at different MAFs without arbitrarily choosing the threshold for the test. 
Not only does the variable threshold test allow for detection of signals, but it also provides 
information regarding the MAF of variants contributing to the signal. We assessed the 
significance of tests by predicting empirical P-values through permutation of case/control pool 
status and a FDR cutoff of 0.2. We performed a variable threshold version of the tests in which, 
for every possible allele count in the study under 5% , we calculated a Z-score for all variants at 
that allele count threshold and below.  
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For C-alpha we calculated the Z-scores at each threshold using the following formula as 
outlined in Neale et al., 2011: ! = !/ ! 
where 
! = [ !! − !!!! ! − !!!! 1− !! ]!!!!  
and  
푐 = !(!)!"# !!!! ! − !!! ! − !!! 1− !! !!(!|!,!!)!!!!  
In T, we calculate the variance for each variant where yi is the alternate allele case count for the 
i’th variant, ni is the total alternate allele count, and p0 is the proportion of the case samples in 
our case pools out of the total number of samples. The variable c standardizes T. Here m(n) is the 
number of variants with n alternate allele counts. The sum is taken for each possible case 
alternate allele count u. 
 For Burden tests, we calculated the Z-scores at each threshold using the following 
formula as outlined in Price et al., 2010: 
! = ! !!!!!"(!! − !!)/ (!!!!!")!!!!!!!!!
!/!!
!!!
!
!!!  
At each threshold, we summed the alternate allele counts in cases C where i indexes variants and 
j indexes pools. The symbol ! is the pools case status and ! is the mean case status. 
We performed 10,000 permutations of case status per test. For all Z-scores in the test and 
permutations at each threshold, we divided by the standard deviation of the permuted Z-scores at 
each threshold to standardize the Z-scores across the MAF thresholds. We determined P-values 
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by comparing the maximum Z-scores from the 10,000 permutations to the maximum Z-score for 
the test. We assessed significance of tests using a FDR cutoff of 0.2. 
 
ENCODE Regions 
For DNase I hypersensitive sites, we used DNase-seq Peaks from SK-N-SH_RA and 
BE2_C cell lines to represent neuronal positions and from Gliobla, HA-h and NH-A cell lines to 
represent glial positions. For transcription factor binding sites (TFBS), we used combined TFBS 
SPP-based peaks and TFBS PeakSeq peaks from SH-SY5Y and SK-N-SH_RA to represent 
neuronal positions and from Gliobla, U87 and NH-A to represent glial positions. SH-SY5Y data 
contained peaks for transcription factor GATA2, and SK-N-SH_RA data contained peaks for 
CTCF, p300, RAD21, USF1, and YY1. Gliobla contained peaks for CTCF and POL2, U87 
contained peaks for NRSF, and NH-A contained peaks for CTCF. For histone modifications 
sites, we used H3K27me3, H3K36me3, and H3K4me3 peaks in SK-N-SH_RA cell lines to 
represent neuronal positions and used H3K27ac, H3K27me3, H3K36me3, H3K4me1, and 
H3K4me3 peaks in NH-A cell lines to represent glial positions. 
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Results 
 
 
 
Sequence Data 
We collected 1,612,969,337 reads with 166,135,841,711 base calls across all 77 pools, 
averaging 20,947,654 reads per pool. An average of 57.1% of the reads were mapped on target 
with a range of 45.0% to 62.3% and a standard deviation of 3.3%. On average 44.4% of base 
calls were within the target regions. Average per base coverage per individual was 79.2 with a 
range of 59.8 to 87.3 and a standard deviation of 5.0. 79.7% of bases within targets had Phred ≥ 
20 and the average coverage for Phred  ≥ 20 was 59.4 (44.6 to 69.2 range, 3.7 standard 
deviation). 98.4% of the target bases had at least 20x average coverage per sample. 
We called 9,928 variants using CRISP (Bansal, 2010). After filtering pools based on 
excess singleton detection and poor correlation with known genotypes for the pool, 7,029 
variants and 1,656 samples (840 cases and 816 controls) remained. We removed 426 variants for 
low quality scores (see methods) and an additional 24 variants that fell below our inclusion 
threshold of 20x coverage for a total of 6,579 passing variants. Finally, we only tested variants 
with MAFs 5% or lower, excluding an additional 1,129 variants. Of the 5,450 remaining variants 
2,944 were singletons that are not tested in C-alpha because they do no provide a deviation from 
an expected distribution, as random chance will always have a singleton allele in either a case or 
a control sample. This left 5,450 variants for Burden testing (Price et al., 2010) and 2,506 
variants for C-alpha testing (Neale et al., 2011). There were 348 indels called out of the 5,450 
variants. For doubletons and greater 182 variants of 2,506 were indels. Of the 6,579 variants that 
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passed filtering 3,881 were novel and 2,698 were previously observed. Figure 9 shows the 
distribution of variants by MAF.  
 
Figure 9: Histogram of MAF in variants that passed all filtering and that are less than 5% MAF. 
 
Summary 
Our testing strategy involved applying the Burden and C-alpha pooled association tests to 
sets of the variants that passed filtering. We selected the variant sets to probe and clarify the role 
of rare variation in schizophrenia. Starting from the most general set, every variant in the study 
less than 5% MAF, we then narrowed the focus to sets of study-wide coding and non-coding 
variants. We used conservation scores to group non-coding variants into low conservation and 
high conservation positions to better understand the signal in the non-coding regions and we also 
used conservation scores to compare the sets of coding and non-coding variants with the most 
highly conserved base positions. We tested variants grouped into sets by ENCODE (Rosenbloom 
et al., 2013) functional elements. Finally, to detect the influence of rare variation specific to a 
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particular locus, we tested locus variant sets individually. The Burden pooled association test 
measures an aggregation of excess variants with unidirectional effects, either protective or 
damaging (see Methods). C-alpha measures an aggregation of excess variants in the test with 
bidirectional effects, both protective and damaging. These tests are complimentary in that a 
Burden tests indicates the general direction of effect for the excess risk-altering variation in the 
set, but will not detect an even mixture of excess protective and damaging variation while C-
alpha will detect the mixture, but not indicate a general direction of effect for excess risk-altering 
variation. No Burden tests were significant at 20% FDR so all results that follow refer to C-alpha 
results. The results for all tests are summarized in Table 2. 
Table 2: Test results. Tests with a (B) indicate the test was a Burden test otherwise it is a C-alpha test. 
General Tests MAF 
Allele 
Count 
Variants ≤ 
Threshold Zmax P-value q-value 
Entire Target 0.09% 3 986 4.31 0.011 0.111 
Entire Target (B) 0.12% 4 4072 -2.78 0.519 0.601 
Non-coding 0.09% 3 828 3.89 0.024 0.111 
Non-coding (B) 0.12% 4 3424 -2.99 0.285 0.453 
Coding 0.09% 3 158 3.32 0.071 0.182 
Coding (B) 2.17% 72 823 -1.48 1.000 0.744 
High Impact 0.06% 2 8 1.36 0.489 0.587 
High Impact (B) 0.33% 11 89 -0.77 1.000 0.744 
Constrained 4.20% 139 1277 3.28 0.089 0.205 
Constrained (B) 1.99% 66 2798 -1.32 1.000 0.744 
       
Locus Tests       
MIR137 2.90% 96 116 1.59 0.476 0.580 
MIR137 (B) 0.12% 4 176 -1.60 0.995 0.743 
ITIH3/4 0.72% 24 94 2.49 0.188 0.353 
ITIH3/4 (B) 0.27% 9 226 -1.62 0.977 0.739 
TRIM26 1.42% 47 38 2.15 0.128 0.271 
TRIM26 (B) 0.06% 2 30 -1.75 0.752 0.686 
CSMD1 1.45% 48 669 3.44 0.040 0.142 
CSMD1 (B) 0.09% 3 1327 -1.45 1.000 0.744 
ANK3 0.09% 3 143 3.22 0.062 0.168 
ANK3 (B) 4.26% 141 787 -1.85 0.989 0.742 
CNNM2-NT5C2 2.20% 73 143 1.94 0.421 0.550 
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CNNM2-NT5C2 (B) 1.06% 35 308 1.14 1.000 0.744 
STT3A 2.11% 70 20 2.54 0.176 0.338 
STT3A (B) 2.11% 70 56 -0.91 0.998 0.743 
CACNA1C 0.21% 7 232 1.44 0.608 0.638 
CACNA1C (B) 0.09% 3 577 -2.11 0.944 0.733 
TCF4 0.30% 10 299 4.06 0.023 0.111 
TCF4 (B) 4.23% 140 1017 2.29 0.885 0.720 
       
ENCODE Elements Tests       
DNase glial 0.06% 2 61 2.28 0.322 0.483 
DNase glial (B) 3.11% 103 386 -2.70 0.246 0.417 
DNase neuronal 4.20% 139 118 3.96 0.031 0.127 
DNase neuronal (B) 0.09% 3 197 -1.94 0.880 0.719 
Histone glial 2.90% 96 586 4.15 0.022 0.111 
Histone glial (B) 0.06% 2 880 -2.36 0.836 0.708 
Histone neuronal 0.09% 3 135 3.70 0.048 0.153 
Histone neuronal (B) 2.32% 77 657 -1.41 1.000 0.744 
TFBS glial 2.39% 79 104 2.26 0.266 0.436 
TFBS glial (B) 2.39% 79 235 -2.02 0.808 0.701 
TFBS neuronal 2.87% 95 231 4.26 0.015 0.111 
TFBS neuronal (B) 0.03% 1 298 1.50 1.000 0.744 
       
Conservation Median Split Tests       
phastCons high conservation 1.12% 37 855 3.17 0.105 0.234 
phastCons high conservation (B) 0.21% 7 1849 -1.11 1.000 0.744 
phastCons low conservation 3.05% 101 994 4.07 0.013 0.111 
phastCons low conservation (B) 0.12% 4 1710 -2.97 0.285 0.453 
phyloP high conservation 0.06% 2 297 3.41 0.054 0.160 
phyloP high conservation (B) 0.21% 7 1855 -1.58 1.000 0.744 
phyloP low conservation 3.14% 104 1009 4.11 0.017 0.111 
phyloP low conservation (B) 0.12% 4 1697 -2.86 0.387 0.529 
SiPhy-pi high conservation 0.06% 2 286 3.37 0.058 0.164 
SiPhy-pi high conservation (B) 0.12% 4 1715 -1.28 1.000 0.744 
SiPhy-pi low conservation 0.09% 3 438 4.28 0.010 0.111 
SiPhy-pi low conservation (B) 0.12% 4 1709 -3.24 0.110 0.242 
       
Functional Domain Tests       
CUB-CSMD1 1.39% 46 118 4.86 0.005 0.111 
CUB-CSMD1 (B) 0.66% 22 304 1.43 0.999 0.744 
Sushi-CSMD1 0.09% 3 8 2.34 0.227 0.397 
Sushi-CSMD1 (B) 0.12% 4 53 1.26 0.988 0.741 
       
High Conservation Tests       
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phyloP > 2 1.12% 37 186 3.44 0.050 0.156 
phyloP > 2 (B) 0.06% 2 403 -2.36 0.582 0.628 
phyloP > 2 coding 0.06% 2 15 2.93 0.088 0.204 
phyloP > 2 coding (B) 0.06% 2 135 -2.19 0.509 0.596 
phyloP > 2 non-coding 1.12% 37 129 4.09 0.019 0.111 
phyloP > 2 non-coding (B) 0.06% 2 268 -1.19 1.000 0.744 
 
Study-Wide Tests 
Our first test was an analysis of all 2506 variants detected in our entire target set. At a 
threshold of ≤ 0.09% MAF, in our study size representing variants with 2 or 3 alternate alleles 
detected in the sample as a whole, we observe a significant excess of variance in the distribution 
of alleles between cases and controls compared to random expectation because these alleles are 
uniquely or preferentially represented in one phenotypic group or the other (P = 0.011, q = 
0.111, Figure 10). At this low MAF, alleles contributing to signal are uniquely present in cases or 
controls, for example both doubleton alleles being seen in cases or all three tripleton alleles being 
seen in controls. 
  We were interested in comparing independent contributions from coding and non-coding 
sequences, so we split the variants into a non-coding variants group and an exon and UTR 
variants group for further testing. Testing each set independently, we again detect peak signals at 
≤ 0.09% MAF in both non-coding (P = 0.024, q = 0.111) and coding (P = 0.071, q = 0.182) 
subsets (Figure 10). For both our coding and non-coding variants we observed very rare variation 
driving the signal of excess unequal case/control allele distribution. 
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Figure 10: Z-scores at each MAF threshold for all, coding plus UTRs and non-coding variation. For each MAF 
threshold we calculate a Z-score for all variants at the threshold and below. Each point on the line represents the Z-score 
for all variants at that MAF and below. The horizontal dotted lines are the levels for which only 5% of the permutation Z-
max scores are greater than or equal to for the test. 
 
 
Conservation 
In addition to the peak signal at ≤ 0.09% MAF that we formally tested, the graph of non-
coding variant results in Figure 10 also suggests that non-coding alleles with higher MAF from 
3.14% to 4.05% are also differentially distributed between cases and controls. We examined 
these signals further by dividing the non-coding variants into more and less highly conserved sets 
using a median split for each of three different measures of conservation, phyloP, SiPhy-pi, and 
phastCons (Garber et al., 2009; Pollard, Hubisz, Rosenbloom, & Siepel, 2010). Scores had been 
generated using the three methods from Multiz alignments!(Blanchette et al., 2004) from 46 
species of the placental mammals phylogenetic tree (Murphy et al., 2001). PhyloP and SiPhy-pi 
measure conservation at a single base while phastCons incorporates flanking bases. Unlike 
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phastCons and phyloP, SiPhy-pi allows for detection of biased substitution patterns. The 
consideration of the flanking regions in phastCons makes it useful for identifying regions of 
conservation, instead of positions of conservation.  The consideration of biased substitution 
patterns in SiPhy-pi makes it useful for such special cases. We consider phyloP to be the most 
general measurement of conservation because it measures conservation at a single base and 
considers any base changes across species as evidence for lower conservation. We examined the 
similarity of conservation scores, and since the phastCons measure generally takes values of 0 or 
1, our comparison was limited to phyloP and SiPhy-pi scores. PhyloP and SiPhy-pi scores show 
a reasonable degree of correlation (0.548, Figure 11). Points lying off the diagonal are due to the 
biased substitution detection in SiPhy-pi for certain sites that increases the conservation score 
compared to phyloP, which does not detect these patterns. 
 
Figure 11: Scatter plot of phyloP scores vs. SiPhy-pi scores for all 6,579 post-filtering variants. The correlation between 
the scores is 0.548. The fanning off the diagonal trend is due to detection of biased substitution patterns using SiPhy-pi. 
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For the phyloP (Figure 12) high and low conservation split, we observe a significant 
excess of variance in the distribution of alleles at 0.06% MAF (P = 0.054, q = 0.160) for the 
highly conserved positions and ≤ 3.14% MAF (P = 0.017 q = 0.111) for the less conserved 
positions. The less conserved base position variant set shows a clear excess of signal coming 
from higher MAF compared to the more conserved base position variant set which has a peak 
signal from doubleton variants.  
Variants at 0.06% MAF (P = 0.058, q = 0.164) at highly conserved positions and ≤ 
0.09% MAF for less conserved positions (P = 0.010, q = 0.111), defined by SiPhy-pi (Figure 
13), were also unequally distributed between cases and controls. While still having a rarer signal 
in more conserved positions, the SiPhy-pi score MAF difference is not as large as seen in 
phyloP.  
Variants ≤ 3.05% MAF in less conserved positions as defined by phastCons (P = 0.013, q 
= 0.111) were unequally distributed between cases and controls (Figure 14).  Variants in highly 
conserved phastCons positions had a similar pattern to phyloP with a lower MAF peak signal 
(1.12%), but this test was not significant. Although the test was not significant, the lower MAF 
peak signal in more conserved positions still matched the patterns seen in phyloP and SiPhy-pi. 
Across the three measures of conservation, we observe a clear pattern of significant 
differences in allelic distributions between cases and controls coming from higher frequency 
variants at less conserved positions. This is strongest and most evident in the most general 
conservation measure, phyloP. For the variant sets of the more conserved positions, the signal is 
predominately from very rare doubleton and tripleton variants using phyloP and doubleton 
variants using SiPhy-pi. 
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Figure 12: Z-scores for high and low phyloP scores 
 
 
Figure 13: Z-scores for high and low SiPhy-pi scores 
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Figure 14: Z-scores for high and low phastCons scores 
 
Narrowing the analysis further to consider only variants in the positions defined as 
constrained in the 29 mammal comparison (Lindblad-Toh et al., 2011), which includes all coding 
sequences, we detected a near significant difference (q = 0.205) in the distribution of alleles 
between cases and controls for ≤ 4.20% MAF (Figure 15). This result is weak support for excess 
unequal case/control allele distribution from much more common variation contributes to the 
signal from constrained regions. 
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Figure 15: Z-scores for all constrained, coding and UTR variations 
 
High Impact and High Conservation 
We also tested frameshift, splice site, nonsense variants in addition to missense variants 
predicted to be damaging by Condel (Gonzalez-Perez & Lopez-Bigas, 2011) as a high impact 
variation group. The test was not significant possibly due to the low number of variants available 
to test with only 8 doubleton variants contributing to its peak Z-score. We pursued a different 
strategy to select potentially high impact variation by testing coding and non-coding variants 
with a base position phyloP score above 2, which indicates a less than 1% chance that the base 
would appear as conserved by chance. This strategy allows comparison of coding and non-
coding variants at equally high levels of conservation. The distribution of variant phyloP scores 
is shown in Figure 16, with line indicating a phyloP score of 2. We observe more variants at 
these highly conserved positions in non-coding regions (390) than in coding regions or UTRs 
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(193). For all variants in this category we observed a significant signal ≤ 1.12% MAF (P = 
0.050, q = 0.156). When splitting these variants into coding and non-coding groups we observed 
a significant signal at ≤ 1.12% MAF (P = 0.019, q = 0.111) and nonsignificant peak signal (q = 
0.204) at 0.06% MAF respectively (Figure 17). The high conservation coding test only included 
15 doubleton variants contributing to its peak Z-score so the test is relatively underpowered. 
While we observed that rare variation contributes the predominant signal for the more conserved 
half of non-coding variation, the non-coding variants in the most highly conserved positions 
yield a peak signal at a higher MAF. The higher MAF of the C-alpha signal peak for the most 
highly conserved non-coding positions is not consistent with the very rare peak for the more 
conserved half of non-coding positions. An explanation for this may be that the highly conserved 
set only represents a small subset of the more conserved half of non-coding positions (151 
variants out of 1039) and therefore is less stable of a signal. We find the non-coding variants at 
highly conserved positions have more significant differences in allelic case/control distribution at 
higher MAFs than in coding variants at equivalently conserved positions. It is possible that the 
conservation of these positions in non-coding sequences does not reflect the same level of 
importance as in coding sequences, allowing risk-altering variants for schizophrenia to be 
maintained in the population at a higher MAF and lower effect size at these sites. 
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Figure 16: PhyloP base scores for variation in coding regions and UTRs and variation in non-coding regions. The dotted 
vertical line marks a phyloP score of 2. While the proportion of variation in coding regions and UTRs at bases phyloP > 2 
(0.194) is higher than the proportion found in non-coding regions (0.070), the number of non-coding variants at bases 
with phyloP > 2 (390) is greater than the number found in coding regions and UTRs (193). 
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Figure 17: Z-scores for all highly conserved (phyloP > 2) also showing the split into coding and non-coding variation. 
 
ENCODE Regions 
 We also assigned the variants to DNase I hypersensitive sites, TFBS, and histone 
modification sites found to be active in neuronal and glial cells in the ENCODE project. Details 
on how we defined ENCODE test regions are in the methods section.  
DNase I hypersensitive sites had a significant excess unequal case/control allele 
distribution (≤ 4.20% MAF, P = 0.031, q = 0.127) but DNase I hypersensitive regions in glial 
cells did not (Figure 18). The excess of unequal distribution of case/control alleles was 
predominantly in more common variants for the DNase I neuronal variant set. 
Transcription factor binding sites had a significant excess unequal case/control allele 
distribution for neuronal cell regions (≤ 2.87% MAF, P = 0.015 q = 0.111) (Figure 19) but did 
not for glial cell regions. For variants in the neuronal cell TFBS the excess in unequal 
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distribution of case/control alleles was at a lower, but still relatively common, MAF than in 
DNase I hypersensitive sites. 
We observed significant excess unequal case/control allele distribution for histone 
modification sites observed in neuronal cells (≤ 0.09% MAF, P = 0.048, q = 0.153) and glial 
cells (≤ 2.90% MAF, P = 0.022, q = 0.111) (Figure 20). The signal of excess unequal distribution 
of case/control alleles is very different in neuronal histone modification sites compared to glial 
histone modification sites, with the former being from rare variants (case and control, only 
doubletons and tripletons). The results of the tested ENCODE regions require careful 
interpretation. We include methylated histone markers that activate transcription, H3K4me1, 
H3K4me3, and H3K36me3, and repress transcription, H3K27me3. For acetylation, we include 
H3K27ac, which increases openness of chromatin. C-alpha testing is bidirectional, allowing for 
detection of bidirectional signals as may be seen in a combination of transcription activating and 
repressing histone modification sites. In histone modification sites from glial cell lines we 
observe more common variation in the ≤ 2.90% MAF range contributing to excess unequal 
distribution of case/control alleles, but for neuronal cell line sites this signal comes from very 
rare variation ≤ 0.09% MAF. For our geneset, variants in neuronal histone modification sites 
may be under heavier selection than variants in glial histone modification sites. 
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Figure 18: Z-scores for DNase I hypersensitive sites from neuronal cell lines 
 
Figure 19: Z-scores for transcription factor binding sites from neuronal cell lines 
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Figure 20: Z-scores for histone modification sites from neuronal and glial cells 
 
Locus Tests 
 We further examined each of the 9 loci separately. We observed significant results for 
three individual loci, ANK3, a joint schizophrenia and bipolar risk locus that encodes the voltage-
gated sodium channel associated Ankyrin G, the miR-137 regulated transcription factor TCF4, 
and complement control related gene CSMD1. ANK3 (Figure 21) had the lowest allele frequency 
threshold for its C-alpha signal (≤ 0.09% MAF, P = 0.062, q = 0.168). The peak C-alpha signal 
for TCF4  (Figure 22) was significant at ≤ 0.30% MAF (P = 0.023, q = 0.111) and the peak C-
alpha signal for CSMD1 (Figure 23) was significant at ≤ 1.45% MAF (P = 0.040, q = 0.142). 
CSMD1 has an interesting property in that it consists primarily of two repeating functional 
domains, the CUB domain and the Sushi domain. We tested the variants in these domains 
separately and observed a significant excess unequal distribution of case/control alleles in the 
CUB domains (≤ 1.39% MAF, P = 0.005, q = 0.111) but not the Sushi domains. The CUB 
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domains of CSMD1 had the most significant P-value from the study. The Sushi domains had 
relatively few variants (28) in the test set which may have contributed to the low signal. CSMD1 
is an interesting gene because of its role in cancer and inflammation. Expression of CSMD1 
mRNA cloned in rats is primarily found in developing CNS and epithelial tissues(Kraus et al., 
2006). The CSMD1 protein was detected in the neuronal growth cone in developing fetal rat 
brains. 
 
Figure 21: Z-scores for ANK3 
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Figure 22: Z-scores for TCF4 
 
 
Figure 23: Z-score for CSMD1 and its functional domains, CUB and Sushi 
0
1
2
3
4
0 1 2 3 4 5
MAF (%)
Z−
sc
or
e
−1
0
1
2
3
4
5
0 1 2 3 4 5
MAF (%)
Z−
sc
or
e
Group
CSMD1
CUB
Sushi
 52 
 
 
 
Discussion 
 
Summary 
 Our results show that rare variation influencing schizophrenia risk is not limited to the 
coding exons and UTRs included in current exome sequencing studies. The high levels of 
conservation across species in these select non-coding positions increase the chance that changes 
to the sequence affect gene function and disease risk. It is significant that these signals were also 
observed in regions selected based on common variant associations from GWAS. As in IBD 
(Rivas et al., 2011) we observe rare variation in the loci selected through common variation 
association, independently supporting the involvement of these loci in schizophrenia. More loci 
implicated in recent GWAS (Ripke et al., 2013) (S. W. G. o. t. P. G. Consortium, 2014) should 
be explored for causal rare variation to help elucidate the mechanism by which these loci affect 
disease and to assess the additional impact of rare variation.  
 
Rare Non-coding Variation in Disease 
In our study 84% of the variation < 0.1% MAF range contributing to the signal was in 
non-coding regions and the signal was maintained when coding and non-coding variants were 
tested separately. The addition of non-coding sequence could greatly improve the quality and 
amount of information obtained from sequencing studies of all diseases. Exome studies could be 
expanded for targeted deep sequencing in non-coding functional and conserved sequences 
beyond the exome, until whole genome deep sequencing for large sample sizes is cost-effective. 
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The observation of rare non-coding variation is not unique to our study. Sequencing of the IL4 
locus in 72 African American (AA) asthma cases and 70 AA controls revealed an excess of 
private non-coding rare variants in cases (Haller, Torgerson, Ober, & Thompson, 2009). The 
authors suggest these rare variants cannot be reliably imputed and therefore sequencing of non-
coding regions is important for identifying rare genetic variants contributing to disease.  A study 
of 100 genes implicated in asthma using 450 cases and 515 controls found IL12RB1 to be a 
susceptibility locus with predominately non-coding variant signals in both AA and European 
Americans (EA) (Torgerson et al., 2012). Limited work has been done on non-coding rare 
variation is schizophrenia. A study sequencing 27 kb from six schizophrenia candidate genes, 
AKT1, BDNF, DRD3, DTNBP1, and NRG1, found an excess of rare non-coding variants in 37 
cases compared to 25 controls (Winantea et al., 2006). The researchers determined the 
enrichment by calculating Tajima’s D-value for the cases and the controls. A small Tajima’s D-
value in cases compared to controls indicated an excess of rare variants in the case sample.  
Our work is the first large study discovering influence of non-coding rare variants in 
several loci for schizophrenia. The evidence from asthma, an autoimmune disorder, supports our 
finding in schizophrenia, a disease for which the immune system is also implicated. 
 
Locus Tests 
 The loci that we found significantly associated with schizophrenia were ANK3, TCF4 and 
CSMD1. ANK3 was first identified as a bipolar disorder locus in a GWAS of 4,387 cases and 
6,209 controls (Ferreira et al., 2008). The PGC-1 study was the first to observe a joint association 
for combined bipolar disorder cases and schizophrenia cases compared to controls (Ripke S, 
2011). In a study of 516 Han Chinese schizophrenia cases and 400 controls, ANK3 was 
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implicated as an independent schizophrenia risk locus (Yuan et al., 2012). More recently, coding 
variation in ANK3 has been associated with autism (Bi et al., 2012).  
Several studies of ANK3 and its protein product Ankyrin-G and their effect on 
neurodevelopment and cognitive performance have been published. Ankyrin-G is a scaffolding 
protein that localizes to the axon initial segment and nodes of Ranvier of neurons (Kordeli, 
Lambert, & Bennett, 1995). Knockdown of ANK3 was found to increase β-catenin in the nucleus, 
causing an increase in neural progenitor proliferation (Durak et al., 2014). The mechanism 
suggested for the increase in β-catenin is that functional ankyrin-G interacts with E-cadherin and 
Wnt. One study found damaging mutations in the ANK3 gene in patients with severe cognitive 
deficits (Iqbal et al., 2013). The authors found all isoforms of ANK3 disrupted by a balanced 
translocation in one patient with autism, attention deficit hyperactivity disorder (ADHD), 
sleeping problems, and borderline intelligence. They also found a frameshift mutation in the 
longest isoform segregating in a family with moderate intellectual disability. Reasoning that 
memory deficits are common to disorders such as intellectual disability, autism and ADHD, the 
authors disrupted Ank2, the closest homolog to human ANK3 in Drosophila. They observed a 
significant reduction of short-term memory in the flies. The authors observed normal learning 
and other behaviors, and concluded that Ank2 was crucial for properly functioning memory in 
Drosophila. A study of cognitive deficits in 173 patients with first episode psychosis found 
association of a common ANK3 allele (allele G of rs1938526) with lower cognitive performance, 
verbal memory, working memory and attention (Cassidy et al., 2014). The authors also observed 
an association between this allele and cortical thinning. An additional study of 163 patients with 
first-episode schizophrenia and 42 controls found association of a common ANK3 allele (allele T 
of rs10994336) with lower accuracy and longer reaction time in a 2-back test, where the 
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participant must log items flashed on a screen in addition to the 2 items before (Zhang et al., 
2014). Our study is the first to implicate rare variation in ANK3 as a risk factor for schizophrenia. 
 TCF4 was first identified as a schizophrenia risk factor in an early GWAS (Stefansson et 
al., 2009). It is a basic Helix-Loop-Helix transcription factor found through knockdown 
experiments to be involved in cell survival, epithelial to mesenchymal transition, and 
neurodevelopment (Forrest, Waite, Martin-Rendon, & Blake, 2013). It has been identified as a 
susceptibility locus for multiple disorders, with common variants identified impacting Fuch’s 
endothelial corneal dystrophy, primary sclerosing cholangitis and, as previously mentioned, 
schizophrenia (Forrest, Hill, Quantock, Martin-Rendon, & Blake, 2014). Our study is the first to 
observe rare variation in TCF4 associated with schizophrenia. Private frameshift, nonsense, 
splice site and missense variants and deletions (CNVs partially covering the gene or completely 
covering the gene) of TCF4 have been found to cause Pitt-Hopkins syndrome (Peippo & 
Ignatius, 2012), a syndrome characterized by intellectual disability and developmental delay. A 
study of smokers and never-smokers taken randomly from the German population found that 
smokers with the rs9960767 risk allele had reduced sensory gating, measured by P50 suppression 
(Quednow et al., 2012). In patients with first episode psychosis, the rs9960767 risk allele has 
also been associated with lower performance in the Reasoning/Problem-Solving domain of the 
WAIS-III and Trail Making Test B (Albanna et al., 2014; Reitan, 1992). There is also evidence 
for correlation of the risk allele in schizophrenia cases with improved cognitive performance. In 
one study schizophrenia cases with the rs9960767 risk allele performed better on the Rey 
Auditory Verbal Learning Test (Helmstaedter, 2001), which measures verbal declarative 
memory (Lennertz et al., 2011). In a Han Chinese sample, schizophrenia cases homozygous for 
the rs2958182 risk allele performed better on cognitive tasks compared to cases with the non-risk 
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allele (Zhu et al., 2013). Han Chinese controls homozygous for the rs2958182 risk allele 
performed worse on cognitive tasks (Zhu et al., 2013). The literature on cognition, schizophrenia, 
and common variant TCF4 loci has been mixed, with some positive effects and some negative 
effects correlated with the risk alleles for schizophrenia patients. 
Our significant TCF4 C-alpha test shows that rare variation has a bidirectional effect. 
Some variants are protective, decreasing schizophrenia risk, and some variants are damaging, 
increasing schizophrenia risk. This is supported by the biology of basic Helix-Loop-Helix 
transcription factors, which may act as transcriptional repressors or activators (Quednow, 
Brzozka, & Rossner, 2014). In Forrest et al., 2013, TCF4 knockdown caused increased 
expression for 494 genes and decreased expression for 710 genes (Forrest et al., 2013). With 
such a great number of upregulated and downregulated genes, damaging variants in TCF4 seem 
likely to perturb regulation of a large number of individual loci with potentially significant 
impact on neurodevelopment and later function. Such focal changes in a single transcription 
factor gene could potentially mimic and interact with the effects of numerous variants from other 
loci on schizophrenia risk, given the strong support for a highly polygenic and distributed genetic 
structure.  
A study of 512 schizophrenia cases and 270 controls searched for causal rare variation in 
a small, ultraconserved non-coding 227 bp region of TCF4 with evidence for enhancer activity 
(UC435) (Gonzalez-Penas et al., 2014). The researchers did not find any variants in UC435. In 
our 840 case and 816 control sample we found only one singleton in UC435, in a case sample at 
chr18:53089932 (novel A allele, G reference). Our TCF4 locus test included many other non-
coding regions and our results suggest an aggregation of low frequency TCF4 variation 
impacting schizophrenia risk.  
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 CSMD1 is a transmembrane protein, and contains repeating and alternating CUB and 
Sushi (complement control protein or CCP) domains. Sushi domains are involved in complement 
inhibition for the classical and lectin pathways of the complement system. The complement 
system is the immune system’s first line defense against foreign antigens. The 15 Sushi tandem 
repeat inhibits complement deposition on eukaryotic cell surfaces (Escudero-Esparza, 
Kalchishkova, Kurbasic, Jiang, & Blom, 2013). The CUB domain is a 110-residue domain 
structure, composed of a β-sandwich fold. Many proteins have CUB domains with a Ca2+ 
binding site, including CSMD1 (Gaboriaud et al., 2011).  
CSMD1 is a tumor suppressor gene implicated in multiple cancers, including squamous 
cell carcinoma, colorectal cancer, melanoma, lung, head and neck, and breast cancer. One study 
showed copy number losses in CSMD1 in head and neck squamous cell carcinoma, cutaneous 
squamous cell carcinoma, cutaneous basal cell carcinoma, lung and breast cancers (Ma et al., 
2009). Another study showed that 87% of squamous cell carcinoma cell lines had increased 
methylation upstream of the CSMD1 transcription start site, associated with gene silencing, 
compared to normal upper aerodigestive epithelial cells (Richter, Tong, & Scholnick, 2005). A 
study has also found low levels of CSMD1 expression in melanoma (Tang, Wang, Guo, Han, & 
Wang, 2012). Somatic nonsynonmous mutations have been observed in late stage colorectal 
cancer (Farrell et al., 2008) and in colorectal cancer diagnosed at an early age (Shull et al., 2013), 
indicating a role for CSMD1 the development of aggressive, metastatic disease.  
In addition to schizophrenia and cancer, CSMD1 has been implicated in bipolar disorder 
through GWAS (Sklar et al., 2008) (Baum et al., 2008) (W. Xu et al., 2014) and autism through 
CNVs (Glancy et al., 2009) and exome sequencing in families (Cukier et al., 2014). Involvement 
in neuropsychiatric disorders is supported by the observation that the CSMD1 gene cloned in rats 
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was expressed primarily in the developing CNS and epithelial tissues, and its protein was 
enriched in fetal rat nerve growth cones (Kraus et al., 2006).  
The CSMD1 risk variant implicated in schizophrenia (rs10503253) has been studied for 
impact on several neurocognitive effects. A study of 1,149 healthy Greek Caucasian males found 
additive effects of the risk allele for poorer general cognitive ability (IQ), strategy formation, 
spatial and visual working memory, set shifting, target detection, and planning for problem 
solving (Koiliari et al., 2014). Similar results were found in a study of Irish and German 
schizophrenia cases and controls with the risk allele being associated with poorer IQ and 
memory function (Donohoe et al., 2013). With evidence for the role of CSMD1 in 
neurodevelopment, and its impact on cognitive abilities, investigators used MRI and fMRI to 
measure the effect of the rs10503253 genotype on grey and white matter volume and activity 
during a spatial working memory task (Rose et al., 2013). The authors found that the risk allele 
was significantly associated with reduced cortical activations in the right middle occipital gyrus, 
a region involved in spatial working memory. No structural differences in brain volume were 
found based on genotype.  
CSMD1 rare variation has not been strongly implicated in neuropsychiatric disorders. 
There is no evidence of CSMD1 rare variation in bipolar disorder and there is only weak 
evidence of CSMD1 rare variation in autism. CSMD1 variants were observed in two separate 
autism families in a 40 family study (Cukier et al., 2014). Also, unlike TCF4’s association with 
Pitt-Hopkins syndrome, CSMD1 rare variation is not associated with any syndromes. The only 
strong evidence for rare variation in CSMD1 impacting disease has been somatic mutations in 
cancer.  
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The CSMD1 signal we observed differs from both ANK3 and TCF4 in that it is a less rare 
signal, with a signal maximizing when alleles up to 1.45% MAF are included in the test. This 
result is consistent with the lack of strong association of other neuropsychiatric disorders with 
rare variation in CSMD1. Even though the variation in CSMD1 driving the signal in our study is 
not very rare, our results support association of the gene with schizophrenia at a lower MAF than 
PGC-1 (≤1.45% compared to 19%). Our observation of a signal coming specifically from the 
CUB domain is a first for schizophrenia. No functional work has been done on the CUB domain 
or CSMD1 in schizophrenia, but based on the literature and our results it may be a promising 
candidate gene and functional domain. 
 
Functional Class Tests 
 In our study, we found variations within ENCODE functional elements from neuronal 
and glial cell lines to be associated with schizophrenia.  We tested functional elements active in 
neuronal cell lines because neurons are the primary cells involved in cognition and central 
nervous system (CNS) function. Our analysis of functional elements active in neuronal cell lines 
shows that variation in transcription factor binding sites, DNase I hypersensitive sites, and 
especially rare variation from histone modification sites influences schizophrenia risk.  
We tested functional elements active in glial cell lines because glia support neurons and 
the three major classes of glial cells, oligodendrocytes, microglia and astrocytes, have been 
implicated in schizophrenia (Goudriaan et al., 2013) (Frick, Williams, & Pittenger, 2013). 
Dysfunction in oligodendrocytes, glial cells that produce the myelin in the nervous system, has 
been shown to impact synaptic function and white matter integrity in the brain (Takahashi, 
Sakurai, Davis, & Buxbaum, 2011) and an analysis of common variant p-values from the PGC-1 
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schizophrenia study (Ripke S, 2011) found the oligodendrocytic gene set pathway associated 
with schizophrenia (Duncan et al., 2014). Variation in oligodendrocyte specific genes involved 
in myelin production affects cognitive performance and the integrity of white matter tracts 
(Voineskos et al., 2013). Microglia are macrophages in the CNS involved in innate immunity. 
There is evidence that microglia play a role in schizophrenia through neuroinflammation (Monji 
et al., 2013). Astrocytes support the nervous system in several ways, including by providing 
structural and nutritional support for neurons and aiding synaptic function (Takahashi & Sakurai, 
2013). One study observed a significant decrease in astrocyte density in the cingulate gray 
matter, cingulate white matter and midline of the corpus callosum in schizophrenia patients 
compared to controls (Williams et al., 2013). Loss of function in astrocytic receptors and gap 
junctions of astrocytes may contribute to cognitive impairment in schizophrenia. (Mitterauer, 
2011).  
The data we used in our glial DNase I hypersensitive sites, transcription factor binding 
sites, and histone modification sites analyses were all from astrocyte-derived cell lines: Gliobla, 
HA-h, NH-A, and U87 (Project, 2014). At the time of this study, ENCODE data for microglia 
and oligodendrocytes were unavailable. We also found damaging and protective variation (C-
alpha test) in histone modification sites active in the cell lines. Literature supports the effect of 
epigenetic modulation of histone deacetylase inhibitors on schizophrenia (Cha, Kudlow, 
Baskaran, Mansur, & McIntyre, 2014) and we included acetylated histone regions in our glial 
histone modification test. H3K4me3, a trimethylation of histone H3 at lysine 4 we included in 
our glial and neuronal histone modification test, is an active mark for transcription and is 
implicated in increased expression of synapsin genes in bipolar disorder and major depression 
(Cruceanu et al., 2013). The signal in histone modification sites is very different in neuronal cell 
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line regions compared to glial cell line regions. The signal from neuronal cell line regions is 
driven by much rarer alleles (≤ 0.09% MAF) than the signal from glial cell line regions (≤ 2.90% 
MAF), possibly indicating that variation in neuronal cell line regions is under heavier selection 
pressure. 
 
Limitations 
The results of this study must be interpreted with several limitations. We performed 
sequencing in pools of 24 cases or 24 controls. This method is efficient, but did not allow us to 
incorporate LD into our analysis. We used permutation testing to compensate for the effects of 
LD on the test statistic. Pooled sequencing may also introduce some error in allele count calling. 
Our careful consideration of concentration while pooling, careful quality control, and improved 
probabilistic allele count calling mitigates this risk. Also, we were not able to include every 
constrained site within our target region due to the 500kb limit using the specific capture 
approach we chose, but our target and bait design did include 84.5% of all constrained sites at 
10% FDR across 29 mammals (Lindblad-Toh et al., 2011) within our target intervals. 
 
Future Studies 
 Although pooled association tests can identify associated loci, future studies should use a 
much larger sample size, probably on the order of the largest GWAS size, to find single rare 
variant associations. As our data show, future sequencing studies should include non-coding 
regions because they may contain useful data. Lower capture and library preparation costs will 
make individual sample sequencing more affordable. Future studies should consider using 
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individual sample sequencing to eliminate the limitations of pooled sequencing studies discussed 
above. The ultimate future study will use low cost, individual, whole genome sequencing.  
There are many influences on the heritability of schizophrenia that remain unexplained 
and that may be uncovered by increasing sample size and amount of the genome sequenced. The 
discovery of individual rare variants associated with schizophrenia will promote a new series of 
functional studies to elucidate the mechanism by which the variants affect schizophrenia risk. 
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